Shilajit in a standardized composition produces a significant improvement in several cardiovascular parameters including RI, AIx and SEVR. Further, significant reductions in malondialdehyde and increases in nitric oxide levels are provided suggesting improvement in endothelial function. Shilajit may be used to reduce inflammatory biomarker HsCRP levels significantly compared to baseline and placebo. Additionally, Shilajit can provide significant improvement in lipid parameters including total cholesterol, LDL-C, and HbA1c (%) Inhibition of platelet aggregation using Shilajit performed using ADP as aggregant also provides highly significant inhibition of platelet aggregation compared to baseline and with placebo. Thus, Shilajit may be used for improvement of endothelial function and to help reduce cardiovascular morbidity, particularly for the diabetic individual.
